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Background COVID-19 is an inflammatory syndrome 
caused by novel coronavirus SARS- CoV-2. Symptoms 
range from mild infection to severe acute respiratory 
distress syndrome (ARDS) requiring ventilation and 
intensive care. At the time of data collection, UK cases 
were around 300 000 with a fatality rate of 13% 
necessitating over 10 000 critical care admissions; now 
there have been over 4 million cases. Nutrition is important 
to immune function and influences metabolic risk factors 
such as obesity and glycaemic control, as well as recovery 
from acute illnesses. Poor nutritional status is associated 
with worse outcomes in ARDS and viral infections, yet 
limited research has assessed pre- morbid nutritional 
status and outcomes in patients critically unwell with 
COVID-19.
Objectives Investigate the effect of body mass index 
(BMI), glycaemic control and vitamin D status on outcomes 
in adult patients with COVID-19 admitted to an intensive 
care unit (ICU).
Methods Retrospective review of all patients admitted 
to a central London ICU between March and May 2020 
with confirmed COVID-19. Electronic patient records data 
were analysed for patient demographics; comorbidities; 
admission BMI; and serum vitamin D, zinc, selenium 
and haemoglobin A1c (HbA1c) concentrations. Serum 
vitamin D and HbA1c were measured on admission, or 
within 1 month of admission to ICU. Primary outcome of 
interest was mortality. Secondary outcomes included time 
intubated, ICU stay duration and ICU- related morbidity.
Results Seventy- two patients; 54 (75%) men, mean 
age 57.1 (±9.8) years, were included. Overall, mortality 
was 24 (33%). No significant association with mortality 
was observed across BMI categories. In the survival arm 
admission, HbA1c (mmol/mol) was lower, 50.2 vs 60.8, 
but this was not statistically significant. Vitamin D status 
did not significantly associate with mortality (p=0.131). 
However, 32% of patients with low vitamin D (<25 IU/L) 
died, compared with 13% of patients with vitamin D levels 
>26 IU/L. Serum zinc and selenium, and vitamin B
12 and 
folate levels were measured in 46% and 26% of patients, 
respectively.
Discussion/conclusion Increased adiposity and 
deranged glucose homeostasis may potentially increase 
risk of COVID-19 infection and severity, possibly relating 
to impaired lung and metabolic function, increased 
proinflammatory and prothrombotic mechanisms. Vitamin 
D deficiency may also associate with poorer outcomes 
and mortality, supporting a possible role of vitamin D in 
immune function specific to pulmonary inflammation 
and COVID-19 pathophysiology. There are plausible 
associations between raised BMI, glycaemic control, 
vitamin D status and poor prognosis, as seen in wider 
studies; however, in this service evaluation audit during 
the first wave of the pandemic in the UK, with a limited 
data set available for this analysis, the associations did not 
reach statistical significance. Further research is needed 
into specific nutritional markers influencing critical care 
admissions with COVID-19.
INTRODUCTION
As COVID-19 cases continue to rise world-
wide, so does the role of nutritional factors 
on the agendas of government, public health, 
primary and secondary healthcare bodies. 
One aspect of clinical importance is the role 
of nutrition in critical care, particularly how 
specific baseline parameters of nutritional 
status may influence illness severity, morbidity 
and mortality. At the time of data collection 
and analysis in September 2020, UK cases 
have exceeded 300 000 with a fatality rate 
of ~13% necessitating >10 000 critical care 
admissions.1 It is therefore paramount we 
learn from previous and current practice to 
What this paper adds
 ► This snapshot audit in a London ICU from the first 
peak of the COVID-19 pandemic adds to the body 
of evidence associating overnight/obesity as a risk 
factor of disease severity and mortality in COVID-19.
 ► Further data suggesting baseline vitamin D status 
may influence severity of COVID-19 as higher mor-
tality was observed in individuals with vitamin D de-
ficiency (<25 nmol/L).
 ► This highlights baseline nutritional parameters that 
are easily obtainable in the critical care setting and 
suggests additional nutritional markers worthy of 
further research.
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improve our understanding and clinical management of 
COVID-19 in the wake of the continuing pandemic if we 
are to minimise future morbidity and mortality.
As SARS- CoV-2 is a novel coronavirus, it is not yet fully 
understood which specific nutritional parameters are most 
impactful on disease severity and outcomes. However, it is 
well established that nutrition plays a key role in immune 
function and several macronutrients and micronutrients 
are required for key physiological processes during infec-
tion.2 Globally, clinical data collection has highlighted 
certain nutritional factors that may influence outcomes 
of COVID-19.3 However, there are limited data published 
that relate to the nutritional status of patients on admis-
sion to critical care units, thus we present data from this 
context.
Audit rationale and selected parameters
The rationale for this audit was to present data on nutri-
tional parameters of patients with COVID-19 from a 
real- world intensive care unit (ICU) setting. We wanted 
to determine whether there were any clear associations 
between mortality and nutritional parameters that (1) 
are commonly measured in clinical practice, and (2) have 
been identified as possible risk factors for worse outcomes 
in the care of inpatients with COVID-19. Parameters of 
particular interest were obesity, glycaemic control and 
vitamin D status.
Obesity: body mass index
It has been demonstrated that higher body mass index 
(BMI) and obesity are associated with poorer outcomes 
in COVID-19.4 One large cohort study examined the 
factors associated with COVID-19- related hospital deaths 
in the linked electronic health records of 17 million adult 
National Health Service (NHS) patients. It found that 
the risk of death increased with the degree of obesity: 
fully adjusted HR was 1.05 for obese class I, increasing 
to 1.92 for obese class III (BMI ≥40 kg/m2).5 A key 
consideration in critical care is that increased body mass 
adversely impacts pulmonary function by reducing expi-
ratory reserve volume, functional capacity and respiratory 
system compliance.6 These factors, in addition to tech-
nical airway difficulties associated with obesity, are delete-
rious for patients who require mechanical ventilation and 
precipitate further respiratory complications. Increased 
adiposity is also associated with increased proinflamma-
tory cytokines that have been implicated in the pathogen-
esis of COVID-19.2
Type 2 diabetes and glycaemic control: haemoglobin A1c
Other established risk factors for worse COVID-19 
outcomes include cardiometabolic diseases: type 2 
diabetes mellitus (T2DM), hypertension and dyslipi-
daemia.5 7 A whole population study of England during 
the first peak of the pandemic indicated that people with 
T2DM had a twofold increased risk of inpatient COVID-
19- related deaths relative to people without diabetes.8 
This study also indicated significance when adjusting for 
cardiovascular disease and T2DM that remained inde-
pendent risk factors for mortality when further adjusting 
for age, ethnicity and social deprivation. Although 
glycaemic control targets have remained controversial 
in the critical care setting, it is established that baseline 
insulin sensitivity and subsequent glycaemic control can 
influence mortality in the general population.9 It could 
therefore be speculated that individuals with T2DM 
presenting with COVID-19 may benefit from tighter 
glycaemic control.
Vitamin D status: 25-hydroxyvitamin D
Another area of interest is the role of micronutrients and 
how individual baseline levels may impact morbidity and 
mortality. Vitamin D status has attracted much attention 
as a secosteroid with biological roles in immune func-
tion and anti- inflammatory, antifibrotic and antioxidant 
effects.10 Vitamin D insufficiency (defined as serum levels 
25–50 nmol/L) and deficiency (<25 nmol/L) across the 
UK are estimated at approximately 23% in people aged 
19–64 years increasing in prevalence in the months of 
January–March to 40%.11 It is recognised that vitamin D 
status across the UK significantly reduces in the winter 
months due to the reliance of skin synthesis and the 
lack of required ultraviolet B exposure from sunlight. 
National and localised lockdowns have led to reduced 
outdoor activity and subsequently less sun exposure 
in many groups thus likely further impacting vitamin 
D levels. Across Europe, ecological studies indicate an 
inverse correlation between estimates of vitamin D status 
and COVID-19 incidence and mortality.12
An association between vitamin D status and respi-
ratory tract infections, tuberculosis and chronic 
obstructive pulmonary disease is long- established and 
supplementation in individuals with low vitamin D levels 
has improved outcomes in interventional studies.13 
There is a plethora of mechanistic pathways linking 
vitamin D to pulmonary immune function that could 
have a role in COVID-19 pathophysiology. While robust 
interventional trials are awaited in this area, given the 
high prevalence of suboptimal vitamin D levels in the 
general population, and the additional risk during 
autumn and winter months, exploring the link between 
baseline vitamin D status and COVID-19 severity could 
further our understanding of how to optimally supple-
ment in high- risk groups.
Other micronutrients
Several other micronutrients are essential to healthy 
immune responses and many may have a role in 
COVID-19 outcomes, particularly in deficiency. The 
practice of measuring serum levels of other micronutri-
ents varies greatly between individuals. Nonetheless, for 
completeness of data regarding nutritional parameters, 
we also wanted to present recorded levels of zinc, sele-
nium, magnesium, vitamin B12 and folate for all patients 
in whom these were measured.
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Aims
We aimed to investigate the relationship between BMI, 
glycaemic control and vitamin D status, respectively, on 
outcomes in patients admitted to the ICU with COVID-19 
pneumonia. Primary measure was mortality. Secondary 
measures included time intubated, ICU stay duration and 
ICU- related morbidity.
Methods
We undertook a retrospective review of all patients 
admitted to a West London ICU between 18 March and 
18 May 2020 with confirmed COVID-19, as confirmed 
clinically and by a positive oropharyngeal or nasopha-
ryngeal SARS- CoV-2 PCR test. No patients were excluded 
from analysis.
Data were extracted from the electronic patient data-
base. The following data were collected: patient demo-
graphics; comorbidities; BMI on admission (using ICU 
bedscale or patient database); serum vitamin D concen-
tration; mean weekly random plasma glucose and plasma 
haemoglobin A1c (HbA1c). Serum vitamin D concen-
tration and HbA1c were taken on admission, or within 
1 month of admission to ICU. The serum C reactive 
protein (CRP) was also recorded at the same time point 
as vitamin D. The requirement for insulin, steroid, antibi-
otic, intravenous water- soluble vitamin concentrate (the 
preparation used in this department was Pabrinex, which 
contains thiamine, riboflavin, pyridoxine hydrochlo-
ride, ascorbic acid, nicotinamide and glucose) and renal 
replacement therapy at any time point during the admis-
sion was also recorded. The primary outcome measure 
was mortality. Secondary outcome measures included the 
time intubated, the length of ICU stay and ICU- related 
morbidity.
Statistical analysis was undertaken using SPSS V.24 
(IBM). Statistical significance was set as p<0.05. Contin-
uous parametric data sets were compared by the t- test, 
and non- parametric data sets by the Mann- Whitney U 
test. Categorical data were compared using Χ2 test. Data 
are presented as mean (±SD) or median (IQR).
RESULTS
In total, 72 patients were included in the service evalu-
ation (see online supplemental table 1 for summary of 
demographics). Of these, 48 survived (68%) and were 
discharged from ICU. Fifty- four patients (75%) were men, 
and mean age was 57.1 (±9.8) years. Nineteen patients 
had no comorbidities documented on admission. The 
most common comorbidities were hypertension (40%), 
T2DM (26%) and chronic kidney disease (20%). Six 
patients (8%) received oral nutrition only during their 
ICU admission, 58 (81%) required enteral nutrition 
(57 via nasogastric tube (NGT), 1 gastrostomy), 3 (4%, 
including 2 of those who also required NGT) required 
parenteral nutrition, and these data were not recorded 
for 7 patients (10%).
Body mass index
Mean BMI was 29.5 kg/m2 (SD ±5.7) for the survival 
group and 28.2 kg/m2 (SD ±4.8) for the non- survivors. 
No patients were admitted with a BMI <18.5 kg/m2. No 
significant difference in mortality was observed across 
different BMI categories, p=0.589 (table 1).
HbA1c and glycaemic control
Admission HbA1c was determined by either electronic 
patient records from the 1- month period prior to admis-
sion or, if unavailable, was taken at admission. Mean HbA1c 
levels were less overall in the survival group than in the 
non- survivors, 50.2 mmol/mol (SD ±17.0) vs 60.8 mmol/
mol (SD ±34.7), but this was not statistically significant, 
p=0.284. There was no statistical difference in outcome 
between patients who took insulin prior to admission and 
those with diet- controlled or tablet- controlled T2DM.
Weekly mean plasma glucose control was also assessed 
across the cohort of 71 (one individual’s data were not 
fully available and therefore were omitted) and indicated 
no statistically significant difference between survivors 
and non- survivors. Overall, mean plasma glucose was 
deemed well controlled across both groups with mean 
glucose levels of 8.1 mmol/L (SD ±1.9) and 8.9 mmol/L 
(SD ±2.3), respectively (table 2).
Table 1 BMI categories and primary outcome of survival
BMI, kg/m2
Survived, 
n=48 Died (n=24) P value
18.5–24.9 (%) 8 (61.5) 5 (38.4) 0.589
25.0–29.9 (%) 22 (64.7) 12 (35.3)
30.0–34.9 (%) 10 (71.4) 4 (28.6)
35.0–39.9 (%) 4 (57.1) 3 (42.9)
≥40.0 (%) 4 (100.0) 0 (0.0)
BMI, body mass index.
Table 2 Mean plasma glucose control during the total 
length of stay
Week
Mean plasma glucose, mmol/L (SD)
Survived Died P value
1 (n=71) 8.0 (2.2) 9.0 (2.7) 0.125
2 (n=66) 8.3 (2.2) 9.3 (2.4) 0.132
3 (n=47) 7.9 (1.9) 9.1 (2.4) 0.063
4 (n=32) 8.0 (1.8) 9.3 (2.7) 0.112
5 (n=19) 8.2 (2.1) 8.8 (2.2) 0.618
6 (n=7) 7.9 (2.3) 11.0 0.267
7 (n=5) 7.4 (1.7) 8.7 0.551
8 (n=2) 7.4 (1.8) – –
9 (n=1) 8.4 – –
Entire stay (n=71) 8.1 (1.9) 8.9 (2.3) 0.083
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Vitamin D status
A limited analysis of vitamin D status was possible as 51 
(71%) of the 72 patients included had a recorded vitamin 
D level either on admission or within 1 month of admis-
sion. If this was taken on admission, it was ensured that 
a correlating CRP was taken to aid interpretation. We 
subcategorised this measure into three groups as per UK 
national cut- offs for deficient, insufficient and sufficient 
serum concentration of 25- hydroxyvitamin D (25(OH)
D) (table 3). Overall, only 20% of patients had sufficient 
vitamin D levels. When comparing vitamin D levels across 
all three groups, no significant difference in mortality was 
observed, p=0.131. Twenty- five individuals were deficient 
in vitamin D (<25 nmol/L), of whom 8 died (32%) and 
17 survived. There was a similar rate of vitamin D insuf-
ficiency (26–50 nmol/L) in both groups (38% of survi-
vors, 27% of non- survivors). Furthermore, of those who 
died, none had sufficient levels of vitamin D prior to ICU 
admission.
Further analysis calculated the mean BMI of each 
group subcategorised by vitamin D status (table 4). This 
indicated those with deficiency or insufficiency were, on 
average, in the obese category. In comparison, the eight 
patients with sufficiency had an average BMI of 26.7 kg/
m2, which is considered overweight. This may represent 
a trend between higher BMI and lower vitamin D levels, 
but this was not statistically significant (p=0.238). We did 
not account for possible confounders known to impact 
COVID-19 outcomes, such as age, male sex, ethnicity or 
socioeconomic status, and this further limits the interpre-
tation of this analysis.
Analysis of variance
We also analysed the correlation between CRP when 
serum concentration of 25(OH)D and found no signifi-
cant correlation (figure 1).
Other micronutrients
In this group, selenium and zinc were measured in 33 of 72 
(46%) patients. For selenium, the mean serum level was 
0.88 µmol/L (range 0.64–1.6 µmol/L; normal reference 
range). For zinc, the mean serum level was 10.2 µmol/L 
(range 3.0–20.1 µmol/L; normal reference range).
Folate and vitamin B12 levels were measured in 19 of 
72 (26%) patients. The mean vitamin B12 level was 803 
ng/L (range 285–2000 ng/L; normal reference range). 




Our patient demographics for this audit aligned with 
the national picture in ICU at the time of data collec-
tion comparing with the Intensive Care National Audit 
& Research Centre (ICNARC) data. This was comparable 
for age and gender and can be considered nationally 
representative in terms of ethnicity, with similar propor-
tions of white, Asian and black patients1 (table 5).
A high percentage of our cohort were both older 
and men observing a higher case mortality rate in male 
patients, consistent with data from across China, Europe 
and the USA.14 This is reflective of higher risk demo-
graphics for COVID-19 corroborating with subsequent 
data establishing age and male gender as individual risk 
Figure 1 Vitamin D status (25(OH)D) in nmol/L versus CRP 
(ng/L). Pearson correlation: −0.053 (p=0.718). 25(OH)D, 
25- hydroxyvitamin D; CRP, C reactive protein.
Table 3 Subcategories of vitamin D levels measured







<25 (deficient) 17 8 0.131
26–50 (insufficient) 15 3
>50 (adequate) 8 0
Χ2 test.
Table 4 Mean BMI as per vitamin D status
25- hydroxyvitamin D (nmol/L)
<25 (n=25) 26–50 (n=18) >50 (n=8) P value
Mean BMI, kg/m2 (SD) 30.7 (5.9) 30.0 (5.7) 26.7 (5.6) 0.238
BMI, body mass index.
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factors that adversely impact severity of disease.1 The 
median age observed in our audit was 57 years in the 
survival arm vs 60 years in the group that did not survive 
which was not statistically significant. However, this adds 
further data indicating increasing age as a risk factor in 
line with current literature. This is likely owing to higher 
rates of pre- existing comorbidities in older age noting 
cardiometabolic conditions as significant risk factors for 
COVID-19 which invariably are more prevalent in this 
population group. Equally factoring in physiological 
age- related decline in immunocompetence should be 
considered.15
Addressing the notion associating male sex with devel-
opment of more severe disease has been observed in 
much larger studies analysed in a global meta- analysis 
which observed increased rate of ICU admissions in men 
seen as a proxy for disease severity.16 The explanation for 
these observations is likely multifactorial and complex 
and has recently been explored in terms of biological, 
behavioural and psychosocial factors.17 Genetic factors 
point towards an increased expression of ACE2 in men, 
as well as sex chromosome- related alterations in immune 
responses when compared with women.18 19 Behavioural 
and psychosocial factors are extensive relating to well- 
established literature linking men to increased risk via 
health behaviours such as increased tobacco and alcohol 
intake along with adherence to public health advice.14 20
Body mass index
Our audit data observed a higher proportion of patients 
in the overweight than obese category in keeping with 
the trend seen in the ICNARC data. However, our data 
were less representative of individuals within BMI range 
18.6–24.9 kg/m2 and while acknowledging this as a limit 
there remained comparable trends to national data sets 
as further outlined. We noted that survivorship data were 
comparable across all BMI groups when cross- referencing 
to the ICNARC data set (table 4). We observed highest 
mortality for those in the obese class II BMI category 
(35.0–39.9 kg/m2) but overall there was no statistically 
significant difference in mortality across BMI ranges, 
including the group in the severely obese category 
(BMI >40.0 kg/m2), who all survived.
While the results may be at odds with other recently 
published data on the relationship of severe obesity and 
disease severity, our data are in keeping with the ICNARC 
data and suggest obesity may increase risk of ICU admis-
sion but is not necessarily an individual marker for poor 
prognosis when used in isolation.4 21
First, there may have been substantial differences in 
the proportion of patients who died in the normal weight 
compared with overweight/obese categories, without 
there being an independent association between BMI 
and mortality, if controlling for the effect of metabolic 
and inflammatory derangements we know to be associ-
ated with worse disease outcomes.22 Data from the UK 
and China demonstrate higher mortality to be associ-
ated with poor glycaemic control, while hypertension has 
been found to be predictive of twofold higher mortality 
in observational data from a cohort in Wuhan.8 23 These 
data suggest that considering BMI status in isolation may 
not be an accurate predictor of death from COVID-19 
and for any future data collection should ensure these 
confounding risk factors are considered and adjusted for 
accordingly.
The observation in patients in the highest BMI cate-
gory is in line with previous meta‐analyses showing 
inverse associations with mortality in ICU patients 
with severe obesity.24 The ‘obesity paradox’ phenom-
enon in critical care, including in patients with acute 
respiratory distress syndrome, describes how a lower 
mortality risk has been observed in obese versus non‐
obese patients.25 26 This could be particularly relevant 
in those patients with COVID-19 requiring prolonged 
ICU admission.27
A number of physiological mechanisms may provide 
an explanation for these observations. Central obesity as 
measured by abdominal girth versus BMI status is a causal 
factor in atelectasis, which can have negative effects on 
pulmonary compliance, functional residual capacity 
and, ultimately, arterial oxygenation.28 Adipose tissue is 
highly metabolically active and obesity is associated with 
increased proinflammatory cytokines and adipokines 
that can lead to dysregulated immune reactions and 
drive inflammatory complications in critical illness.2 This 
indicates BMI alone may be too crude a measure to fully 
illicit the relationship between the implied metabolic/
immune effects differing adipose tissues exert in disease 
state but rather serves as a marker to highlight higher 
risk groups.
Table 5 Patient demographics versus ICNARC data
Characteristic
Audit sample (n=72) ICNARC (n=10 624)
n (%) Median n (%) Median
Age 57–60 60
Gender (%)
  Male 75 (66.7*) 70.2 (58.3*)
  Female 25 (66.6*) 29.8 (64.9*)
Ethnicity
  White 68.1 66.2
  Asian 9.5 15.6
  Black 11.8 9.6
  Mixed/other 10.6 9.6
BMI (kg/m2) (%)
  <18.5 0 0.8
  18.5–24.9 18.0 (61.5*) 25.6 (59.5*)
  25.0–29.9 47.2 (64.7*) 34.4 (57.9*)
  30.0–40.0 29.2 (66.7*) 31.4 (63.6*)
  ≥40.0 5.6 (100*) 7.9 (65.3*)
*Survived critical care.
BMI, body mass index; ICNARC, Intensive Care National Audit & 
Research Centre.
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Glycaemic control and HbA1c
Overall, there was a significantly higher proportion 
of patients with known T2DM in the group who died 
(42%) compared with those who survived (19%). On 
average, HbA1c levels were lower in those who survived 
but this difference did not reach statistical significance. 
This is in line with national findings whereby the largest 
UK- based population study found individuals with T2DM 
had increased odds of in- hospital death with COVID-19 
(OR 2.03) compared with those without.8 It is therefore 
important to not only recognise this high- risk group in 
the critical care setting but equally understand how to 
mitigate some of this risk.
The pathophysiological interplay between COVID-19 
and T2DM is not fully understood; however, it is well 
recognised that infection itself causes metabolic compli-
cations associated with adverse clinical outcomes. 
COVID-19 can precipitate and worsen acute metabolic 
complications associated with both T1DM and T2DM, 
such as diabetic ketoacidosis and hyperglycaemia, which 
may impact mortality rates in this group.29 Mechanistic 
data also support this relationship, whereby it has been 
suggested that hyperglycaemia may upregulate expres-
sion of ACE2 receptor, which is understood to be the 
entry point for the SARS- CoV-2 into cells.30 Other 
proposed mechanisms include altered ACE2 activity, 
chronic inflammation, accelerated endothelial damage 
and hypercoagulable states. All of these might accelerate 
pre- existing end organ damage relating to diabetes, and 
perhaps even more so in individuals with poorer long- 
term diabetic control.5
Targets for glycaemic control within the ICU setting are 
controversial with no definitive consensus on what consti-
tutes ‘optimal control’. There is agreement when under-
standing the detrimental effects of both hyperglycaemia 
and hypoglycaemia but not as to what targets most opti-
mally minimise this.
In this audit, mean plasma glucose levels were within 
a well- controlled range for the duration of both groups 
of ICU stay: 8.1 mmol (SD 1.9) in the survival group and 
8.9 mmol (SD ±2.3) in the non- survivors (p=0.083) with 
an overall mortality rate of 33%. HbA1c levels were lower 
overall in the survival group (50.2 mmol/mol vs 60.8 
mmol/mol), but this association did not reach statistical 
significance. NHS England data comparing COVID-19 
outcomes in patients with higher HbA1c (>86 mmol/mol) 
versus those with HbA1c between 48 and 53 mmol/mol 
found mortality increased with higher HbA1c in patients 
with both T1DM and T2DM.8 In a retrospective analysis 
of patients with T2DM in Wuhan, maintaining in- hospital 
glycaemic variability within 3.9–10.0 mmol/L was asso-
ciated with a significant reduction in adverse outcomes 
and death (1% vs 11%).23 These observations suggest that 
glycaemic control should be an important consideration 
in COVID-19 illness and this should continue to garner 
attention as dexamethasone, with its side effect of hyper-
glycaemia, is included in standard treatment protocols of 
inpatients with COVID-19.
Vitamin D status
In our cohort, we observed a negative correlation between 
vitamin D status and BMI, though this association did 
not reach statistical significance. Beyond the association 
with BMI, vitamin D deficiency (<25 nmol/L) was seem-
ingly associated with increased mortality in the group, 
whereby 8 of the 25 patients with vitamin D deficiency 
died. Conversely, all patients with vitamin D status >50 
nmol/L survived, posing the question as to whether an 
improved vitamin D status contributes to better outcomes 
in the ICU.
Multiple analyses of UK Biobank data have found a 
higher frequency of vitamin D deficiency in patients 
with COVID-19 when compared with population- based 
controls.31 However, these data must be interpreted with 
caution based on a lack of statistical significance when 
adjusted for confounding factors and also due to data 
being largely historical. A study of healthcare workers in 
the UK observed 72% of those with vitamin D deficiency 
tested positive for COVID-19 compared with 51% of those 
without vitamin D deficiency.32 Elsewhere data from Israel 
have shown vitamin D levels estimated between 2010 and 
2019 to correlate strongly with COVID-19 incidence.33 In 
the USA, strong associations have been found between 
lower 25(OH)D levels and increased rate of SARS- CoV-2 
positivity, even after adjusting for confounders.34 These 
studies did not include data on COVID-19 severity.
The association of low vitamin D status with higher BMI 
could be explained by physiological, behavioural, genetic 
and even geographical determinants.35–38 Physiological 
mechanisms include increased storage in adipose tissue 
and altered metabolism, due to reduced metabolite acti-
vation secondary to lower levels of enzymes in adipose 
tissue for hydroxylation. Behavioural factors have been 
particularly noteworthy during the pandemic, particu-
larly in those institutionalised and/or shielding, who as a 
result receive less sun exposure and therefore obtain less 
vitamin D synthesis. Genetic and geographical determi-
nants of vitamin D status based on latitude and ethnicity 
have been well described elsewhere.38
Vitamin D deficiency in critical illness is known to be 
associated with poorer outcomes and supplementation 
has largely been demonstrated as safe; however, defining 
optimum target ranges, clinical assays and measurable 
metabolites has proven difficult.39 Of the extraskeletal 
functions of vitamin D, potential immunomodulatory 
effects have received attention in this patient group. 
Higher vitamin D status is thought to play a role in modu-
lating the inflammatory response, whereas low levels 
appear to be associated with the activation of inflamma-
tory processes.39 The relationship between vitamin D and 
inflammation could be particularly relevant in critically 
ill patients.40 For example, the activation of vitamin D in 
the lung has the potential to induce specific antimicro-
bials and attenuate inflammatory cytokines in response 
to viruses, which is thought to have a role in the case of 
sepsis derived from lung infection.41
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Retrospective meta- analyses from American and Euro-
pean cohorts have indicated low vitamin D status to be 
associated with higher rates of ICU admission in patients 
with COVID-19. Similar to trends observed in our analysis, 
this translated to poorer prognosis, while also highlighting 
significantly lower vitamin D status in ICU compared with 
patients receiving ward- based care.42 Furthermore, in a 
smaller observational study from Italy, a survival analysis 
of patients with COVID-19 admitted to a respiratory inter-
mediate care unit found severe vitamin D deficiency to be 
a predictor of mortality. Those with vitamin D levels <25 
nmol/L had a 50% probability of mortality, compared 
with a 5% risk in those with levels ≥25 nmol/L.43 It is 
of course important to recognise limitations within 
these studies in terms of sample size and methodology. 
However, in the early stages of this pandemic, the role 
of these observations is to provide a basis on which more 
rigorous scientific trials can be designed to help establish 
causal links between such factors and the pathophysi-
ology of SARS- CoV-2.
This increasing depth of observational data has resulted 
in calls for more clinical trials to evaluate a potential ther-
apeutic role of vitamin D in COVID-19. The results of the 
first of these pilot studies have recently been published 
from Spain, which assessed oral supplementation of 
high- dose calcifediol (25(OH)D) alongside combination 
drug therapy in patients with COVID-19, demonstrating 
a reduction in critical care admissions in those supple-
mented.44 Even in the absence of definitive evidence from 
interventional trials, since avoiding vitamin D deficiency 
is already an accepted public health priority in the UK, a 
pragmatic approach would be to test and safely treat for 
suboptimal vitamin D levels in all patients with COVID-
19. There is a clear demand for clinical trials investi-
gating vitamin D supplementation in the prevention of 
COVID-19 in patients with COVID-19 at the earliest stage 
of infection, for example, at the point of receiving a posi-
tive SARS- CoV-2 test result in the community.
Other micronutrients
In this audit, we collected all micronutrient data that 
were measured in this cohort. Serum selenium and zinc 
were measured in only 46% of patients, and vitamin B12 
and folate measured in even fewer, despite these being 
important micronutrients for immune function and their 
measurements being commonly available laboratory tests.
The latest clinical guidelines from the European 
Society for Clinical Nutrition and Metabolism on the 
nutritional management of patients with COVID-19 
highlight the importance of ensuring sufficient levels of 
essential micronutrients to ‘potentially reduce disease 
negative impact’.3 Specifically mentioned are vitamins C, 
D, A, E, B6 and B12, and zinc, selenium and iron, whose 
potential importance is inferred from existing research 
into their roles in immune function and outcomes in 
other infectious diseases. However, there remains a lack 
of evidence from robust interventional studies regarding 
micronutrient management in COVID-19. Furthermore, 
there is no evidence that supplementation is beneficial to 
patients whose levels are already replete.
Other clinical and research considerations
One harsh reality is that, since the majority of patients 
hospitalised with COVID-19 will be elderly and with other 
comorbidities, many will not be offered more intensive 
treatments available in ICU. Therefore, clinical audit 
and trials from outside the ICU setting are also crucially 
important. From a practical perspective, it would be wise 
to frame sensible clinical nutrition interventions such as 
ensuring micronutrient adequacy as the responsibility of 
all healthcare providers caring for patients with COVID-19 
and people at risk.
In the absence of robust interventional data, the nutri-
tional management of patients with COVID-19 in critical 
care remains consensus guided and based on founda-
tional principles. Broadly, these are: routine screening for 
malnutrition; supplementation for insufficiency and defi-
ciency; a ‘food first’ approach, including dietary modifica-
tion for nutritional content and texture; oral nutritional 
supplementation, and escalation to enteral, then paren-
teral, nutrition where appropriate.3 Indeed, ensuring 
adequacy of a single micronutrient is not helpful, and a 
holistic approach to nutritional care, involving a multidis-
ciplinary team of dietitian, nurse, doctor and other allied 
health professionals, is key. An important yet unanswered 
question is how often clinicians should investigate micro-
nutrient levels in anticipation of increased requirements, 
and the presence of systemic inflammation. What is 
accepted is that management of nutrition in critical care 
for patients with COVID-19 must be individualised on a 
case- by- case basis.45
Limitations
The findings of this retrospective analysis are time and 
location specific with limitations in terms of generalis-
ability across different geographical and demographic 
contexts. We have referenced national and international 
data sets for comparisons to guide applicability and 
generalisability to similar regions. The small sample size 
and retrospective nature of the data collection were never 
powered to answer a specific clinical question. Logistical 
barriers such as unprecedented workload and cumber-
some personal protective equipment requirements likely 
impacted accuracy of some measurements, particularly 
accurate weight and height. Indeed, for many parame-
ters, for example vitamin D, a proportion of patients had 
no measurement recorded, which poses a high risk of bias 
to the results in such a small sample. The gaps in our data 
also made it difficult to account for probable confounders 
(age, sex, ethnicity, socioeconomic status) when statis-
tically analysing associations between parameters and 
outcomes. Shared access to electronic community health-
care records provided access to recently recorded data 
where these were not immediately available, for example, 
height and weight, vitamin D level and HbA1c. Selection 
bias was minimised by including all individuals during the 
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time period, but information bias could not be fully miti-
gated against.
Collectively, these limitations also restrict our ability 
to establish any causality (consistency, temporality, speci-
ficity, coherence, experiment and analogy) to define rela-
tionships between nutritional measures and COVID-19 
outcomes. If more nutritional data from similar settings 
are reported, this could allow judgements of consistency 
in relationships across studies in the future.
CONCLUSIONS
This was a single- centre service evaluation of clinical 
and biochemical data relating to nutritional status from 
patients with COVID-19 admitted to ICU during the first 
peak of the 2020 pandemic. We were able to measure 
markers of nutritional status such as serum micronutri-
ents, vitamin D levels and blood glucose more accurately 
when compared with anthropometric measures such as 
height and weight, owing to the unstable nature of this 
patient group and increased clinical pressures during this 
phase of the pandemic. There was a high prevalence of 
T2DM and vitamin D insufficiency/deficiency in this ICU 
cohort and T2DM was more prevalent in those who died 
from COVID-19. Of these, low vitamin D is more straight-
forward to remedy in the acute setting, which supports 
the notion that active detection and correction of vitamin 
D deficiency is warranted in patients with, and at greater 
risk of, COVID-19. However, our data suggest that BMI in 
isolation may not be an accurate predictor of mortality 
in COVID-19 without consideration of a fuller clinical 
picture.
With our evolving understanding of COVID-19 and the 
interplay with nutrition, this presented audit helps to sign-
post to important markers for consideration and advocates 
for better standardisation in nutrition- related measures 
for future audits. Alongside BMI, further anthropometric 
data collection may help refine our risk stratification and 
subsequent public health advice. Equally by measuring 
HbA1c as routine would also help to risk stratify patients in 
and outside of the critical care setting as steroid therapy is 
common practice which subsequently impacts glycaemic 
control and may help to mitigate additional complica-
tions. Further nutritional measures of micronutrient 
status specifically a panel implicated in immune function 
and inflammatory mediation (vitamins C, D, E, zinc and 
selenium) could help to identify individuals at greater 
risk. This would also help to establish if simple, low- risk 
interventions such as targeted micronutrient supplemen-
tation confer clinical benefit and could help to explore 
interventions which are not exclusive to the critical care 
setting. Furthermore, prospective data capture, larger 
observational studies and robust, well- designed interven-
tional trials are required to better establish best practice 
for clinical nutrition approaches and the management of 
nutritional and metabolic comorbidities in patients with 
COVID-19.
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Implications for clinical practice
 ► Baseline nutritional measurements, including capillary glucose, 
haemoglobin A1c (if type 2 diabetes mellitus present) and serum 
micronutrients such as vitamin D, selenium and zinc can be readily 
made in a critical care context in this pandemic.
 ► Obtaining accurate measures of weight and correlating with body 
mass index may help as part of risk stratification when assessing 
clinical prognosis.
 ► This intensive care unit department achieved adequate control of 
capillary blood glucose levels despite significant logistical challeng-
es and with increasing use of dexamethasone may warrant further 
investigation.
 ► Vitamin D status in the critically ill patient is easily obtainable and 
treatment to address deficiency remains in keeping with consensus 
guidelines.
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